Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Jakavi
| Field | Information |
|---|---|
| Medication Name | Jakavi |
| Generic Name | Ruxolitinib |
| Boxed/Label Warning | Serious Infections, Mortality, Malignancies, Thrombosis |
| Purpose | Treatment of myelofibrosis, polycythemia vera, and acute or chronic graft-versus-host disease. |
| Mechanism of Action | Janus-associated kinase (JAK) inhibitor, specifically JAK1 and JAK2. |
| Dosage Forms | Oral tablets |
| Available Strengths | 5 mg, 10 mg, 15 mg, 20 mg, 25 mg |
| Dosage Frequency | Twice daily |
| Common Side Effects | Thrombocytopenia, anemia, neutropenia, bruising, dizziness, headache |
| Serious Side Effects | Infections, anemia, thrombocytopenia, increased cholesterol levels, non-melanoma skin cancer |
| Drug Interactions | Strong CYP3A4 inhibitors or inducers, fluconazole, erythromycin, rifampin, phenytoin. |
| Important Notes | Monitor blood counts regularly. Report any signs of infection immediately to your healthcare provider. |
| Storage | Store at room temperature away from moisture and light. |
| Missed Dose | Take your next dose at your regular time. Do not double the dose. |
| Alternatives | Hydroxyurea, Interferon alfa, Busulfan, Anagrelide |
Jakavi Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Hydroxyurea | Inhibits DNA synthesis | Used in myeloproliferative disorders. |
| Interferon alfa | Immunomodulatory effects | Can be used in polycythemia vera and myelofibrosis. |
| Busulfan | Alkylating agent | Used in chronic myelogenous leukemia and sometimes in myelofibrosis. |
| Anagrelide | Reduces platelet production | Primarily used for essential thrombocythemia but can be considered in some cases. |
Jakavi Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Thrombocytopenia (low platelet count) | Serious infections (e.g., pneumonia, sepsis) |
| Anemia (low red blood cell count) | Progressive multifocal leukoencephalopathy (PML) |
| Neutropenia (low white blood cell count) | Increased cholesterol levels |
| Bruising | Non-melanoma skin cancer |
| Dizziness | Thrombosis (blood clots) |
| Headache | Mortality |
Jakavi Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Myelofibrosis | 5-20 mg twice daily (based on platelet count) | Adjusted based on efficacy and tolerability | Administer orally twice daily. Doses are highly individualized. |
| Polycythemia Vera | 10 mg twice daily | Adjusted based on efficacy and tolerability | Administer orally twice daily. Monitor hematologic parameters. |
| Acute Graft-versus-Host Disease | 5 mg twice daily | May be increased to 10 mg twice daily after 3 days, if tolerated | Administer orally twice daily in patients 12 years and older. |
| Chronic Graft-versus-Host Disease | 10 mg twice daily | Adjusted based on efficacy and tolerability | Administer orally twice daily in patients 12 years and older. |
Jakavi Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $200 |
| Without Insurance (U.S.) | $9500 |
| From Canada | $7500 |
